Our peptide chemistry team is excited to announce a new publication in the journal “Circulation”, which highlights the outcome of a highly successful drug discovery collaboration with the world-class drug discovery group of Merck & Co., Inc., Rahway, NJ, USA.
We are proud for having been part of this exciting and pioneering adventure in the field of macrocycles targeting PPI. This work validates the approach of using peptide libraries from mRNA display technologies for the identification of novel oral therapeutic agents, exemplified by the invention of MK-0616. This oral PCSK9 inhibitor has the potential to be a highly effective cholesterol lowering therapy for patients.